公开(公告)号：US20180064851A1

公开(公告)日：2018-03-08

申请号：US15698429

申请日：2017-09-07

Applicant: Case Western Reserve University ,  Worcester Polytechnic Institute

Inventor： Eben Alsberg ,  Anna D. Dikina ,  Marsha W. Rolle ,  Hannah A. Strobel

IPC: A61L27/38 ,  A61K35/42 ,  A61L27/58 ,  A61K35/32

CPC classification number: A61L27/3817 ,  A61K35/28 ,  A61K35/32 ,  A61K35/42 ,  A61K35/44 ,  A61L27/3804 ,  A61L27/3839 ,  A61L27/3886 ,  A61L27/54 ,  A61L27/58 ,  A61L2300/414 ,  A61L2300/62 ,  A61L2400/12 ,  A61L2430/02 ,  C12M21/08 ,  C12M25/14 ,  C12N5/0655 ,  C12N5/0697 ,  C12N2533/30

Abstract: A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.

公开(公告)号：US09808351B2

公开(公告)日：2017-11-07

申请号：US14875983

申请日：2015-10-06

Applicant: DePuy Synthes Products, Inc.

Inventor： James Edward Kelly ,  Thomas M. DiMauro

IPC: A61F2/44 ,  A61B17/00 ,  A61F2/28 ,  A61F2/46 ,  A61K9/00 ,  A61K49/00 ,  A61L27/12 ,  A61L27/18 ,  A61L27/38 ,  A61L27/50 ,  A61L27/52 ,  A61L27/54 ,  A61F2/30

CPC classification number: A61F2/4455 ,  A61B17/00234 ,  A61F2/28 ,  A61F2/30965 ,  A61F2/441 ,  A61F2/442 ,  A61F2/4425 ,  A61F2/446 ,  A61F2/4465 ,  A61F2/4601 ,  A61F2/4611 ,  A61F2002/2817 ,  A61F2002/2835 ,  A61F2002/30062 ,  A61F2002/30065 ,  A61F2002/30092 ,  A61F2002/30131 ,  A61F2002/302 ,  A61F2002/30224 ,  A61F2002/3023 ,  A61F2002/30308 ,  A61F2002/30383 ,  A61F2002/30451 ,  A61F2002/3055 ,  A61F2002/30556 ,  A61F2002/30579 ,  A61F2002/30583 ,  A61F2002/30586 ,  A61F2002/30604 ,  A61F2002/30622 ,  A61F2002/30841 ,  A61F2002/30971 ,  A61F2002/4475 ,  A61F2002/448 ,  A61F2002/4627 ,  A61F2002/4635 ,  A61F2002/4677 ,  A61F2210/0004 ,  A61F2210/0014 ,  A61F2210/0061 ,  A61F2210/0071 ,  A61F2210/0085 ,  A61F2220/0016 ,  A61F2220/0025 ,  A61F2220/0058 ,  A61F2230/0013 ,  A61F2230/0063 ,  A61F2230/0065 ,  A61F2230/0069 ,  A61F2250/0003 ,  A61F2250/0009 ,  A61F2250/001 ,  A61F2250/003 ,  A61F2250/0065 ,  A61F2310/00011 ,  A61F2310/00179 ,  A61F2310/00365 ,  A61K9/0024 ,  A61K49/006 ,  A61L27/06 ,  A61L27/12 ,  A61L27/18 ,  A61L27/3821 ,  A61L27/3839 ,  A61L27/3847 ,  A61L27/50 ,  A61L27/52 ,  A61L27/54 ,  A61L27/56 ,  A61L2300/252 ,  A61L2300/256 ,  A61L2300/404 ,  A61L2300/414 ,  A61L2300/43 ,  A61L2300/64 ,  A61L2430/02 ,  A61L2430/38

Abstract: An orthopedic device for implanting between adjacent vertebrae comprising: an arcuate balloon and a hardenable material within said balloon.In some embodiments, the balloon has a footprint that substantially corresponds to a perimeter of a vertebral endplate. An inflatable device is inserted through a cannula into an intervertebral space and oriented so that, upon expansion, a natural angle between vertebrae will be at least partially restored. At least one component selected from the group consisting of a load-bearing component and an osteobiologic component is directed into the inflatable device through a fluid communication means.

公开(公告)号：US20170252339A1

公开(公告)日：2017-09-07

申请号：US15447763

申请日：2017-03-02

Applicant: Frequency Therapeutics, Inc.

Inventor： Christopher LOOSE ,  Will MCLEAN ,  Melissa HILL-DRZEWI

IPC: A61K31/506 ,  A61K9/00

CPC classification number: A61K31/506 ,  A61K9/0046 ,  A61L27/3834 ,  A61L27/3839 ,  A61L2430/14

Abstract: The present invention relates to methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells. Specifically, the invention relates to methods of using compounds comprising a 2-pyrimidinylaminoethylamino-2-pyridyl moiety having a Formula I and pharmaceutically acceptable salts thereof.

公开(公告)号：US09752118B2

公开(公告)日：2017-09-05

申请号：US14362775

申请日：2012-12-06

Applicant: Astellas Institute for Regenerative Medicine

Inventor： Kathryn L. McCabe ,  Shi-Jiang Lu ,  Robert P. Lanza

IPC: C12N5/071 ,  C12N5/07 ,  C12N5/16 ,  C12N5/074 ,  C12N5/079 ,  A61K35/30 ,  A61L27/38 ,  A61K9/00 ,  A61K45/06 ,  C12N5/0797

CPC classification number: C12N5/0621 ,  A61K9/0048 ,  A61K35/30 ,  A61K45/06 ,  A61L27/3808 ,  A61L27/3839 ,  A61L27/3895 ,  A61L2430/16 ,  C12N5/0623 ,  C12N2500/60 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/40 ,  C12N2501/415 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/08 ,  C12N2506/45 ,  C12N2533/50

Abstract: This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more “youthful” gene expression relative to cells obtained from donated tissue.

公开(公告)号：US09587222B2

公开(公告)日：2017-03-07

申请号：US10567728

申请日：2004-02-02

Applicant: Hikaru Matsuda ,  Yoshiki Sawa ,  Satoshi Taketani ,  Shigeru Miyagawa

Inventor： Hikaru Matsuda ,  Yoshiki Sawa ,  Satoshi Taketani ,  Shigeru Miyagawa

IPC: C12N15/00 ,  C12N5/00 ,  C12N5/02 ,  C12N5/071 ,  C12N5/077 ,  A61L27/38 ,  A61K35/34 ,  A61K35/12

CPC classification number: C12N5/0658 ,  A61K35/12 ,  A61K35/34 ,  A61L27/3804 ,  A61L27/3834 ,  A61L27/3839 ,  A61L27/3895 ,  A61L2430/20 ,  C12N5/0068 ,  C12N5/0657 ,  C12N2506/02 ,  C12N2506/1392 ,  C12N2513/00 ,  C12N2523/00 ,  C12N2533/40 ,  C12N2539/10

Abstract: The present invention provides a prosthetic tissue or sheet capable of withstanding implantation operations, which can be used in actual operation and can be produced by culture. The present invention also provides a novel therapy which can substitute for cell therapy. Particularly, the present invention provides a method for producing a prosthetic tissue comprising a cell derived from a part other than myocardium and capable of withstanding implantation operation. The above-described objects of the present invention were partially achieved by finding that by culturing cells under specific culture conditions, the cells are unexpectedly organized into a tissue, and the resultant prosthetic tissue is capable of being detached from culture dishes. The present invention also provides a three-dimensional structure applicable to heart, comprising a cell derived from a part other than the myocardium of an adult.

Abstract translation: 本发明提供能够承受植入操作的假体组织或片材，其可以在实际操作中使用并且可以通过培养产生。 本发明还提供了可代替细胞治疗的新型治疗方法。 特别地，本发明提供了一种用于制造假体组织的方法，所述假体组织包含源于除了心肌之外的部分的细胞并且能够承受植入操作。 通过发现通过在特定培养条件下培养细胞，细胞意外地组织成组织，并且所得到的假体组织能够从培养皿中分离，部分实现了本发明的上述目的。 本发明还提供了适用于心脏的三维结构，其包含源自成人心肌之外的部分的细胞。

公开(公告)号：US20160331867A1

公开(公告)日：2016-11-17

申请号：US15154649

申请日：2016-05-13

Applicant: Taipei Veterans General Hospital

Inventor： Shih-Hwa Chiou

IPC: A61L27/36 ,  A61L27/34 ,  A61L27/18

CPC classification number: A61L27/34 ,  A61L27/3641 ,  A61L27/3834 ,  A61L27/3839 ,  A61L27/3891 ,  A61L2430/16 ,  C08L89/00

Abstract: The present invention relates to a method for preparing a multilayered retinal cell implant. The method comprises coating a substrate with laminin to obtain a laminin modified substrate and growing retinal cells derived from stem cells or induced pluripotent stem cells (iPSCs) on the laminin modified substrate, wherein the retinal cells as grown include multiple layers of retinal cells, and provides properties and efficacy facilitating retinal repair.

Abstract translation: 本发明涉及一种制备多层视网膜细胞植入物的方法。 该方法包括用层粘连蛋白涂覆底物以获得层粘连蛋白修饰的底物并生成衍生自层粘连蛋白修饰底物上的干细胞或诱导多能干细胞（iPSC）的视网膜细胞，其中生长的视网膜细胞包括多层视网膜细胞，以及 提供了促进视网膜修复的性质和功效。

公开(公告)号：US20160331507A1

公开(公告)日：2016-11-17

申请号：US15221975

申请日：2016-07-28

Applicant: Histogenics Corporation

Inventor： Sonya Shortkroff ,  Joseph Khoury ,  Laurence J.B. Tarrant ,  Hans P.I. Claesson ,  Robert Lane Smith

IPC: A61F2/02 ,  A61L27/26 ,  A61L27/38 ,  A61F2/28 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  A61F2/08 ,  A61L27/24 ,  A61L27/52

CPC classification number: A61F2/02 ,  A61F2/08 ,  A61F2/28 ,  A61F2/30756 ,  A61F2002/30766 ,  A61F2240/001 ,  A61L27/24 ,  A61L27/26 ,  A61L27/3804 ,  A61L27/3817 ,  A61L27/3834 ,  A61L27/3839 ,  A61L27/3847 ,  A61L27/3852 ,  A61L27/386 ,  A61L27/3873 ,  A61L27/3878 ,  A61L27/52 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  A61L2430/06 ,  A61L2430/20 ,  A61L2430/30 ,  A61L2430/32 ,  A61L2430/34

Abstract: A double-structured tissue implant (DSTI) and a method for preparation and use thereof for implantation into tissue defects. The double-structured tissue implant for differentiation, growth and transformation of cells, stem cells, mesenchymal stem cells and bone marrow stem cells. DSTI comprising a primary scaffold and a secondary scaffold consisting of a soluble collagen solution in combination with a non-ionic surfactant generated and positioned within the primary scaffold.

Abstract translation: 双组织植入物（DSTI）及其制备和使用方法，用于植入组织缺陷。 用于分化，生长和转化细胞，干细胞，间充质干细胞和骨髓干细胞的双重结构组织植入物。 DSTI包括主要支架和由可溶性胶原溶液组合的辅助支架，其与产生并定位在主要支架内的非离子表面活性剂组合。

公开(公告)号：US20160303290A1

公开(公告)日：2016-10-20

申请号：US15074949

申请日：2016-03-18

Applicant: MiMedx Group, Inc.

Inventor： Brenda S. Morse ,  Somaly Sith ,  Randall Spencer ,  John Daniel

IPC: A61L27/38 ,  A61L27/36

CPC classification number: A61L27/3891 ,  A61K35/50 ,  A61L27/3604 ,  A61L27/3687 ,  A61L27/3804 ,  A61L27/3839 ,  A61L27/3878 ,  A61L27/3882 ,  A61L2400/18 ,  A61L2430/12 ,  A61L2430/16 ,  A61L2430/22 ,  A61L2430/32 ,  A61L2430/40

Abstract: Described herein are tissue grafts derived from the placenta that possess good adhesion to biological tissues and are useful in would healing applications. In one aspect, the tissue graft includes (1) two or more layers of amnion, wherein at least one layer of amnion is cross-linked, (2) two or more layers of chorion, wherein at least one layer of amnion is cross-linked, or (3) one or more layers of amnion and chorion, wherein at least one layer of amnion and/or chorion is cross-linked. In another aspect, the grafts are composed of amnion and chorion cross-linked with one another. In a further aspect, the grafts have one or more layers sandwiched between the amnion and chorion membranes. The amnion and/or the chorion are treated with a cross-linking agent prior to the formation of the graft. The presence of the cross-linking agent present on the graft also enhances adhesion to the biological tissue of interest. Also described herein are methods for making and using the tissue grafts.

Abstract translation: 本文描述了衍生自胎盘的组织移植物，其具有对生物组织的良好粘附性并且可用于治愈应用。 在一个方面，组织移植物包括（1）两层或更多层羊膜，其中至少一层羊膜交联，（2）两层或多层绒毛膜，其中至少一层羊膜是交叉的， 连接或（3）一层或多层羊膜和绒毛膜，其中至少一层羊膜和/或绒毛膜交联。 另一方面，移植物由彼此交联的羊膜和绒毛膜组成。 在另一方面，移植物具有夹在羊膜和绒毛膜之间的一层或多层。 羊膜和/或绒毛膜在形成移植物之前用交联剂处理。 存在于移植物上的交联剂的存在也增强了对感兴趣的生物组织的粘附。 本文还描述了用于制造和使用组织移植物的方法。

公开(公告)号：US09463162B2

公开(公告)日：2016-10-11

申请号：US14288767

申请日：2014-05-28

Applicant: FMC Biopolymer AS

Inventor： Jan Egil Melvik ,  Michael Dornish ,  Edvar Onsoyen ,  Astrid B. Berge ,  Terje Svendsen

IPC: A61K35/32 ,  A61K45/00 ,  A61L27/20 ,  C08L5/04 ,  A61K9/10 ,  A23L1/0532 ,  A61K9/16 ,  A61K31/715 ,  A61K31/729 ,  A61L27/34 ,  A61L27/36 ,  A61L27/38 ,  A61L29/08 ,  A61L31/10 ,  A61K31/734 ,  A61K47/36

CPC classification number: A61K9/10 ,  A23L29/256 ,  A61K9/1652 ,  A61K31/715 ,  A61K31/729 ,  A61K31/734 ,  A61K35/32 ,  A61K47/36 ,  A61L27/20 ,  A61L27/34 ,  A61L27/3641 ,  A61L27/3817 ,  A61L27/3839 ,  A61L27/3895 ,  A61L29/085 ,  A61L31/10 ,  A61L2430/36 ,  Y10S435/81 ,  C08L5/04

Abstract: Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactatates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed.

公开(公告)号：US20160243285A1

公开(公告)日：2016-08-25

申请号：US15028618

申请日：2014-10-09

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Kang Zhang ,  Jiagang Zhao ,  Adah Almutairi

IPC: A61L27/38 ,  A61K9/00 ,  C12N5/0797 ,  A61L27/54 ,  A61L27/26 ,  A61K35/30 ,  A61L27/52

CPC classification number: A61L27/3834 ,  A61K9/0046 ,  A61K35/30 ,  A61K35/545 ,  A61L27/24 ,  A61L27/26 ,  A61L27/3804 ,  A61L27/3839 ,  A61L27/52 ,  A61L27/54 ,  A61L2300/64 ,  A61L2430/16 ,  C12N5/062 ,  C12N5/0621 ,  C12N5/0623 ,  C12N2500/33 ,  C12N2500/38 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/39 ,  C12N2501/395 ,  C12N2501/415 ,  C12N2501/42 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/02 ,  A61K2300/00 ,  C08L5/08 ,  C08L1/00

Abstract: The invention provides an in vitro method for producing isolated mammalian primitive retinal stem cells (pRSCs) comprising: (a) culturing isolated embryonic stem cells (ESCs) from a mammal in a cell culture medium that is free of feeder cells, feeder-conditioned medium or serum so as to produce and grow a culture of the isolated ESCs; and (b) contacting the culture of the isolated ESCs so grown with one or more of an inhibitor for Wnt or TGF-β/BMP signaling so as to differentiate the isolated ESCs of (a) into primitive retinal stem cells thereby producing isolated mammalian pRSCs.

Abstract translation: 本发明提供了用于产生分离的哺乳动物原始视网膜干细胞（pRSCs）的体外方法，其包括：（a）在不含饲养细胞的细胞培养基中培养来自哺乳动物的分离的胚胎干细胞（ESC），饲养条件培养基 或血清，以产生和培养分离的ESC的培养物; 和（b）使如此生长的分离的ESC的培养物与一种或多种用于Wnt或TGF-β/ BMP信号传导的抑制剂接触，以将（a）的分离的ESC分化成原始视网膜干细胞，从而产生分离的哺乳动物pRSC 。